Anti-Viral QR-441(a) shown to be effective against pathogens
Quigley Pharma has announced
positive results from a study evaluating their anti-viral compound QR-441(a) in
embryonating egg and VERO E6 cell test models.
was demonstrated as a potential anti-viral agent in reducing Infectious
Newcastle Disease - two pathogens which constantly threaten commercial poultry stocks.
Previous in vitro studies have demonstrated QR-441(a) to be a potent antiviral
agent against H5N1 (Avian Flu).
"The value of a broad spectrum
antiviral addressing multiple viral pathogens in poultry stocks increases the
potential utility of the compound for routine commercial application, as well
its use in the event of more serious H5N1 (Bird Flu) outbreaks," said Dr. Richard Rosenbloom of Quigley
The study was conducted after
receiving industry and veterinary thought leader feedback indicating a need for
a well tolerated broad spectrum antiviral agent against these pathogens which
continue to threaten poultry industries worldwide.
The preliminary data shows that
further study is warranted and that QR-441(a) may have potential in treating
and/or preventing Infectious Bronchitis Virus (IBV) and Newcastle Disease Virus
(NDV). The company will be preparing experiments to validate the significance of
this data in a challenge study in chickens.
For the latest poultry
news, subscribe here
To comment, login here
Or register to be able to comment.